Reig Jofre acquires Bioibérica’s portfolio of finished pharmaceutical and nutraceutical products, representing a turnover of € 26M
Reig Jofre acquires Bioibérica’s portfolio of finished pharmaceutical and nutraceutical products, representing a turnover of € 26M and establishes a strategic agreement to develop the joint health market
As part of its strategic aim of strengthening its presence in both the health care market (consumer healthcare area) and in the disease market (specialty products area), Reig Jofre is focussing on a new therapeutic area, Joint Health and Pain, thus expanding its portfolios of ethical specialty products and consumer healthcare nutraceuticals.
Osteoarticular disease is one of the most prevalent physical complaints in the world: it is estimated that between 5% and 20% of the population suffers from such afflictions, a figure that reaches around 80% in patients aged over 65 in industrialized countries.
- The operation involves the acquisition of the portfolios of medical prescription and consumer healthcare products, the incorporation of specialized human resources and an agreement whereby Bioibérica will continue producing and supplying bulk actives and ingredients to Reig Jofre
- Reig Jofre is diversifying the specialty products area with a new therapeutic area, Joint Health and Pain, a segment which is forecast to grow worldwide in the coming years, and is expanding its product portfolio with medicines for the treatment of osteoarthritis, including the incorporation of leading brands in the Spanish market such as Condrosan and Droglican, and nutraceutical derivatives
- The operation also includes the creation of a strategic agreement to develop the health care market in the joint pain area and to advance in the treatment of osteoarthritis